These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19483281)

  • 41. Deliberate total parathyroidectomy: a potentially novel therapy for tumor-induced hypophosphatemic osteomalacia.
    Bhadada SK; Palnitkar S; Qiu S; Parikh N; Talpos GB; Rao SD
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4273-8. PubMed ID: 23956343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous repletion of phosphorus deficiency in the chronic renal failure patients with severe hypophosphatemia.
    Chang JM; Tsai JC; Hwang SJ; Chen HC; Guh JY; Lai YH
    Kaohsiung J Med Sci; 1997 Sep; 13(9):540-7. PubMed ID: 9348731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cinacalcet in the management of tumor-induced osteomalacia.
    Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
    J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Familial hypophosphatemic rickets].
    Reusz G
    Orv Hetil; 2001 Dec; 142(48):2659-65. PubMed ID: 11778363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
    Raeder H; Shaw N; Netelenbos C; Bjerknes R
    Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
    Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
    Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
    Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
    J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fibroblast growth factor 23--a phosphate regulating hormone].
    Beck-Nielsen SS; Pedersen SM; Kassem M; Rasmussen LM
    Ugeskr Laeger; 2010 May; 172(20):1521-7. PubMed ID: 20483099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypophosphatemia: an evidence-based problem-solving approach to clinical cases.
    Assadi F
    Iran J Kidney Dis; 2010 Jul; 4(3):195-201. PubMed ID: 20622306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging topics in pediatric bone and mineral disorders 2008.
    McKay CP; Portale A
    Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
    Goldsweig BK; Carpenter TO
    Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the parathyroid function in six patients with hypophosphatemic osteomalacia, including a case of tertiary hyperparathyroidism developing during combined oral phosphate and vitamin D therapy.
    Jeon HJ; Kwon SH; Kim SW; Shin CS; Park KS; Kim SY; Cho BY; Lee HK
    Horm Res; 2003; 60(3):127-33. PubMed ID: 12931040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma.
    Reyskens M; Sleurs K; Verresen L; Janssen M; van den Bergh J; Geusens P
    Osteoporos Int; 2015 Jul; 26(7):2039-42. PubMed ID: 25906239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Familial adult onset X-linked hypophosphataemic osteomalacia (report of a family; clinical and experimental studies).
    Radó JP; Haris A; Szebenyi B
    Acta Physiol Hung; 1997-1998; 85(3):199-214. PubMed ID: 10101535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypophosphatemic Rickets.
    Bitzan M; Goodyer PR
    Pediatr Clin North Am; 2019 Feb; 66(1):179-207. PubMed ID: 30454743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia.
    Sato K; Obara T; Yamazaki K; Kanbe M; Nakajima K; Yamada A; Yanagisawa T; Kato Y; Nishikawa T; Takano K
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5564-71. PubMed ID: 11701736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.